Background: Dopamine transporter (DAT) activity is regulated by PKC. Results: We identify Ser7 as a PKC phosphorylation site on DAT and show that phosphorylation conditions and Ser7 mutation alter cocaine analog binding characteristics. Conclusion: Ser7 phosphorylation affects cocaine analog binding by altering DAT conformational equilibrium. Significance: Ser7 phosphorylation of DAT may impact recognition and action of cocaine.
SUMMARY
As an approach to elucidating dopamine transporter (DAT) phosphorylation characteristics, we examined in vitro phosphorylation of a recombinant rat (r) DAT N-terminal peptide (NDAT) using purified protein kinases. We found that NDAT becomes phosphorylated at single distinct sites by protein kinase A (Ser7) and calciumcalmodulin dependent protein kinase II (Ser13), and at multiple sites (Ser4, Ser7, and Ser13) by protein kinase C (PKC), implicating these residues as potential sites of DAT phosphorylation by these kinases. Mapping of rat striatal DAT phosphopeptides by twodimensional thin layer chromatography revealed basal and PKC-stimulated phosphorylation of the same peptide fragments and comigration of PKC-stimulated phosphopeptide fragments with NDAT Ser7 phosphopeptide markers. We further confirmed by site-directed mutagenesis and mass spectrometry that Ser7 is a site for PKCstimulated phosphorylation in heterologously expressed rat and human DATs. Mutation of Ser7 and nearby residues strongly reduced the affinity of rDAT for the cocaine analog (-)-2β-carbomethoxy-3β-(4-fluorophenyl) tropane (CFT), whereas in rat striatal tissue, conditions that promote DAT phosphorylation caused increased CFT affinity. Ser7 mutation also affected zinc modulation of CFT binding, with Ala and Asp substitutions inducing opposing effects. These results identify Ser7 as a major site for basal and PKC-stimulated phosphorylation of native and expressed DAT, and suggest that Ser7 phosphorylation modulates transporter conformational equilibria, shifting the transporter between high and low affinity cocaine binding states.
The dopamine (DA) 4 transporter (DAT) is a phosphoprotein that drives reuptake of extracellular DA following transmitter release and 2 is a target for abused psychostimulants including amphetamine (AMPH), methamphetamine (METH), and cocaine, as well as for agents used to monitor and treat dopaminergic diseases (1) . DAT belongs to the neurotransmitter sodium symporter (NSS) family of transporters that consist of twelve transmembrane (TM) domains with large intracellularly oriented N-and Ctermini (2) . NSS proteins translocate substrates by an alternating access mechanism in which transporters cycle between outwardly facing, occluded, and inwardly facing states (3) . The uptake inhibitor cocaine binds to the outwardly facing form of DAT and prevents structural rearrangements needed for transport, whereas AMPH and METH promote reverse transport (efflux) of preloaded substrate (4) (5) (6) (7) (8) (9) (10) . Forward and reverse DA transport are regulated by interactions of DAT with associated proteins including syntaxin 1A (syn 1A) (11) (12) (13) , and by several kinases including protein kinase C (PKC), calcium-calmodulin dependent protein kinase II (CaMKII), and extracellular signal regulated kinase (ERK) (14, 15) . The overall capacity for DAT-mediated DA clearance is thus established through the integration of multiple molecular inputs, and dysregulation of these processes may play a role in drug addiction and other DA disorders including attention deficit hyperactivity disorder and schizophrenia (16, 17) .
Several properties of DAT including forward and reverse transport, endocytosis, and phosphorylation are affected by PKC and AMPH/METH exposure [reviewed in (18) (19) (20) ], and AMPH/METH-stimulated DA efflux has also been linked to Ca 2+ and CaMKII (7, 21, 22) . Removal of DAT phosphorylation sites does not affect PKC-or AMPH-induced transporter endocytosis or down-regulation (20, 23, 24) , but has been reported to prevent AMPH-induced efflux (6) , suggesting that reverse transport requires transporter phosphorylation. However, our lab has found that deletion of the PKC phosphorylation domain does not impair AMPHstimulated efflux (25) , leaving the mechanistic requirements for phosphorylation in this process unclear.
Thus, although numerous findings support the involvement of PKC and CaMKII in DA transport down-regulation and DA efflux, it remains to be established if these events are dependent upon phosphorylation of DAT by these kinases.
To further explore the role of phosphorylation in DAT regulatory functions, we have sought to identify specific DAT phosphorylation sites and to determine if regulatory kinases act on DAT directly or induce effects indirectly. The phosphorylation pattern of rat (r) DAT is complex, occurring on serine (Ser) and threonine (Thr) at a ratio of ~90% to 10% (26, 27) . Threonine phosphorylation occurs on Thr53, present in a proline-directed motif close to the intracellular end of TM1 (28, 29) , whereas the majority of basal, PKC-induced, and AMPH-induced phosphorylation occurs in a cluster of serines present within the first 21 N-terminal residues (20, 24, 27) . PKC-induced phosphorylation likely occurs at multiple sites, as individual Ser (S) to Ala (A) mutagenesis of distal N-terminal serines does not eliminate 32 PO 4 labeling (30) . Efforts to identify the specific residues phosphorylated within this cluster using site-directed mutagenesis have been extremely problematic due to the difficulties of quantifying partial phosphorylation reductions in the context of different transporter levels. Finally, it is not known if PMA-stimulated phosphorylation of N-terminal serines is catalyzed directly by PKC or by downstream kinases, or if DAT is also phosphorylated by other kinases that regulate transport and efflux.
As one approach to examining these issues, we developed an in vitro phosphorylation assay that uses the recombinant rDAT N-terminal tail sequence (NDAT) as a substrate for purified protein kinases (28) . We previously showed that NDAT is an excellent substrate for multiple kinases that regulate DAT activity and phosphorylation (28) . Here we identify the NDAT residues phosphorylated by protein kinase A (PKA), CaMKII, and PKCα, and extend our findings to the full-length transporter, identifying 3 Ser7 as a PKC-dependent phosphorylation site in rat striatal DAT and heterologously expressed rat and human DAT. Unexpectedly, we found that mutation of Ser7 strongly decreased the binding affinity of DAT for the cocaine analog (-)-2β-carbomethoxy-3β-(4-fluorophenyl) tropane (CFT) and impacted zinc modulation of CFT binding. Conversely, we found in rat striatal tissue that treatments that stimulate transporter phosphorylation increase the affinity of DAT for CFT. These results identify Ser7 as a major phosphorylation site on DAT and support Ser7 phosphorylation as a mechanism for regulation of transporter conformational equilibrium and cocaine binding.
Island, NY ). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or Fischer Scientific (Pittsburgh, PA). Rats were obtained from Charles River Laboratories (Wilmington, MA) and were maintained in compliance with the guidelines established by the University of North Dakota Institutional Animal Care and Use committee and the National Institutes of Health.
NDAT production and phosphorylation -Sitedirected mutagenesis of NDAT was performed on a PTYB plasmid containing WT NDAT (New England Biolabs, Inc.) using appropriate primers (MWG Biotech) and the stratagene Quickchange® Site-Directed Mutagenesis Kit as described previously (28) . Mutations were verified by sequencing (Alpha Biolaboratories, Inc.). In vitro phosphorylation of NDAT with PKA catalytic subunit, CaMKII, and PKCα was performed as previously described (28) using equal amounts of WT and mutant NDAT protein (1.6 µg) for all experiments.
32 P levels were quantified by densitometry, WT levels were set to 100%, and mutant levels expressed as a fraction of WT. Statistical evaluation of phosphorylation levels was performed by ANOVA followed by Dunnett's post hoc test. Unless indicated otherwise results were replicated in 3 or more independent experiments.
Immunoprecipitation and Western BlottingImmunoprecipitation and immunoblotting of rDAT and NDAT were performed as previously described using polyclonal Ab16 or monoclonal antibody 16 (MAb16) directed against rDAT amino acids 42-59 (27, 31) . NDAT and DAT samples were run on 10-20% or 4-20% SDS-PAGE gels respectively.
Site-directed mutagenesis and stable cell expression -Site-directed mutagenesis of rDAT was performed as described above (Quickchange®, Stratagene) and all mutations were verified by dideoxysequencing. WT and mutant rDATs were subcloned into the LZRS-MSneo vector. Stable expressing DAT lines were generated as previously described (32) . Briefly, Phoenix cells (5x10 5 ) were plated and transfected 4 (Fugene-6, Roche) followed by selection (48h) with 4 µg/ml puromycin. After verification of rDAT expression via DA transport assay, Phoenix cells were plated (5x10 6 /100mm dish) in regular medium for viral harvest. After 24h at 32°C the medium containing virus was collected and filtered (45 µM). Viral supernatant with 4 µg/ml polybrene was added to LLC-PK 1 target cells and incubated for 6 h at 32°C. Viral supernatant was then removed and cells were incubated overnight at 37°C followed by viral incubation a second time the next day. After ~48 hours, regular media was replaced with medium supplemented with G418 (250 mg/ml) to select for cells with a stable integration of WT or mutant rDAT. Expression of rDAT was confirmed by western blot analysis.
Phosphorylation of DAT in heterologously expressing cells -LLC-PK 1 cells stably expressing WT or mutant rDATs were grown and used for 32 PO 4 phosphorylation as previously described (20) . Briefly, plated cells were labeled with phosphate-free medium containing 1 mCi/ml 32 PO 4 for 2h at 37°C, followed by application of 1 µM phorbol 12-myristate 13-acetate (PMA) for 30 min. Cells were washed, collected by scraping, and pelleted by centrifugation at 2,000 x g for 5 min at 4°C. The cells were lysed with 10 mM triethanolamine-acetate buffer, pH 7.8, containing 2 mM EDTA, 150 mM NaCl, and 0.1% Triton X-100, and lysates were centrifuged at 4,000 x g for 2 min.
The resulting supernatants were supplemented with SDS to a final concentration of 0.5%, and further centrifuged at 20,000 x g for 30 min to remove insoluble material. Aliquots were assessed by immunoblotting with MAb16 to determine total DAT levels, and equal amounts of DAT were immunoprecipitated with Ab16 followed by SDS-PAGE and autoradiography using Hyperfilm MP.
Band densities were determined by densitometry using images within the linear range of intensities, and stimulated and mutant values were expressed as a fraction of WT basal level set to 100% as previously described (20) .
Phosphorylation values were assessed statistically by ANOVA followed by NewmanKeuls post hoc test. Phosphorylation of DAT in striatal slicesMetabolic phosphorylation of DAT in rat striatal slices was performed by labeling tissue with 1-5 mCi/ml 32 PO 4 for 2h and treating with vehicle or 10 µM oleoyl-2-acetyl-sn-glycerol (OAG) plus 1 µM okadaic acid (OA) for 30 min as previously described (27) . Tissue was lysed with 1% SDS and centrifuged at 20,000 x g for 20 min. The soluble fraction was collected, diluted to 0.1% SDS and immunoprecipitated with Ab16 followed by SDS-PAGE and autoradiography.
Peptide Mapping -NDAT samples phosphorylated in vitro by PKA, CaMKII or PKCα with [γ-
32 P]ATP, and rat striatal DAT metabolically phosphorylated with 32 PO 4 were immunoprecipitated with Ab16 (33) and subjected to SDS-PAGE and autoradiography.
32 P-labeled proteins were excised from the gel, electroeluted, and dialyzed overnight against water. Samples were acetone precipitated, reduced and alkylated, and digested with 20 µg thermolysin for 2h at 60 ˚C followed by addition of 20 µg trypsin at 37˚ C and incubation for 24h. Peptides were suspended in pH 1.9 electrophoresis buffer (acetic acid 7.8%, formic acid 2.5%), spotted onto TLC plates, and separated in the first dimension by electrophoresis for 35 min at 1500V. Plates were dried and peptides resolved in the second dimension by ascending chromatography, dried, and exposed to X-ray film (34) .
Tandem mass spectrometry analysis (LC-MS/MS) -HEK293-hDAT cells were used that stably express YFP-tagged human (h) DAT as previously published (35) . The tag at the Nterminal end of both transporters does not alter their functional characteristics (35, 36) . The cells were cultivated on 10 cm dishes in DMEM complemented with fetal calf serum (10%), Lglutamine (1%), glucose (4.5 g.l -1 ) and gentamycin (50 µg.ml -1 ) at 37°C, 95% humidity and 5% CO 2 . The cells were treated with 0.25 µM OA for 2h and subsequently solubilized in lysis buffer containing 1% Triton X-100, 20 mM Tris-HCl (pH 5 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 5 mM sodium fluoride, 5 mM sodium pyrophosphate and a protease inhibitor cocktail (Roche) on a tube rotator for 2h at 4°C. After centrifugation at 14,000 x g for 30 min at 4°C, the supernatant was collected and incubated overnight with a rabbit anti-GFP polyclonal antibody. Immune complexes were collected with protein G sepharose, washed extensively, and bound proteins eluted in Laemmli buffer (63 mM Tris-HCl, 10% glycerol, 2% SDS, 3% 2-mercaptoethanol, 100 mM dithiothreitol, 0.0025% Bromophenol blue, pH 6.8) at 95°C for 3 min. Eluted proteins were size fractionated on SDS-PAGE gels, visualized by Coomassie Brilliant Blue staining, and the indicated band excised. Gel pieces were destained with 50% acetonitrile in 25 mM ammonium bicarbonate, and dried in a speed vacuum concentrator. After reduction and alkylation of cysteine residues, gel pieces were washed and dehydrated. Dried gel pieces were rehydrated with 25 mM ammonium bicarbonate (pH 8.0) containing 10 ng/µl trypsin (Promega, Madison, WI) and incubated for 18 hrs at 37°C. The digested peptide mixtures were extracted with 50% acetonitrile in 5% formic acid and concentrated in a speed vacuum concentrator for LC-MS/MS. An ion trap mass spectrometer (HCT, BrukerDaltonics, Bremen, Germany) coupled with an Ultimate 3000 nano-HPLC system (Dionex, Sunnyvale, CA, USA) was used for LC-MS/MS data acquisition. A PepMap100 C-18 trap column (300 µm x 5 mm) and PepMap100 C-18 analytic column (75 µm x 150 mm) were used for reverse phase (RP) chromatographic separation with a flow rate of 300 nL/min. The two buffers used for the RP chromatography were 0.1% formic acid/water (buffer A) and 0.08% formic acid/acetonitrile (buffer B) with a 125 min gradient (4-30%B for 105 min, 80%B for 5 min and 4%B for 15 min). Eluted peptides were then directly sprayed into the mass spectrometer to record peptide spectra over the mass range of m/z 350-1500 and MS/MS spectra in informationdependent data acquisition over the mass range of m/z 100-2800. Repeatedly, MS spectra were recorded followed by three data-dependent CID MS/MS spectra generated from four highest intensity precursor ions. The MS/MS spectra were interpreted with the Mascot search engine (Matrix Science, London, UK). Database searches through Mascot were performed with a mass tolerance of 0.5 Da, a MS/MS tolerance of 0.5 Da, three missing cleavage sites, and carbamidomethylation on cysteine, oxidation on methionine, and phosphorylation on serine/threonine were allowed. Each filtered MS/MS spectrum exhibiting possible phosphorylation was manually checked and validated (37, 38) .
[ with shaking at 105 rpm, followed by treatment with vehicle or 1 µM OA plus 10 µM OAG for an additional 30 min. Oxygen (95% O 2 , 5% CO 2 ) was gently blown across the top of the plate during the incubation. The slices were homogenized with a Polytron PT1200 homogenizer (Kinematica, Basel, Switzerland) for 8s and centrifuged at 3,000 x g for 3 min at 4°C. The resulting supernatant was centrifuged at 17,000 x g for 12 min and the pellet was resuspended in modified Krebs phosphate buffer (126 mM NaCl, 4.8 mM KCl, 16 mM potassium phosphate, 1.4 mM MgSO 4 , 10 mM glucose, 1.1 mM ascorbic acid, and 1.3 mM CaCl 2 , pH 7.4) to 20 mg/ml original wet weight (o.w.w.). Triplicate samples of membranes were incubated on ice with 1-300 nM [ 3 H]CFT in modified Krebs phosphate buffer for 2h at 4°C followed by rapid vacuum filtration using a Brandel tissue harvester over Whatman GF/B glass fiber filters soaked for 1 h in 0.1% BSA. Nonspecific binding was determined in the presence of 100 µM cocaine. Filtered samples were assessed for radioactivity by liquid scintillation counting. B max and K d values were determined using Prism 3 software by nonlinear regression, and values were analyzed for statistical significance using Student's t-test. Figure  1A shows the amino acid sequence of NDAT, which contains all of the residues in the intracellular N-terminal domain of rDAT up to the beginning of TM1. We previously showed that NDAT is robustly phosphorylated in vitro by PKA, CaMKII, and PKCα, and here we undertook the identification of the phosphorylation sites for these kinases. Because of the large number of potential phosphate acceptors in the sequence (8 Ser and 4 Thr), we first determined the phosphoamino acid content for each condition using 2D TLC. Results show that each of these kinases phosphorylate NDAT exclusively on serine (Fig. 1B) .
RESULTS

Identification of PKA, CaMKII, and PKCα phosphorylation sites on NDAT -
To identify the specific serines phosphorylated we generated NDATs possessing individual S→A mutations at residues 2, 4, 7, 12, and 13, focusing on the N-terminal Ser cluster phosphorylated in vivo (20, 27) . Phosphorylation of NDAT by PKA was eliminated in the S7A mutant whereas phosphorylation by CaMKII was eliminated in the S13A mutant ( Fig. 2A) , strongly suggesting that PKA and CaMKII phosphorylate NDAT exclusively on Ser7 and Ser13, respectively. PKCα phosphorylation of NDAT was more complex, as 32 P labeling was not abolished by any of the individual S→A mutations (Fig. 2A) . Quantification of band intensities relative to the WT protein showed no statistically significant reduction in phosphorylation for any of the mutants, although trends toward reduction were seen for S4A (87 ± 6% of WT) and S7A (74 ± 6% of WT).
Accordingly, we generated various NDAT double and triple S→A combinations for further PKCα phosphorylation analysis ( Fig. 2B and 2C ). Phosphorylation levels were significantly reduced for S4,7A NDAT (34 ± 8% of WT) (p<0.05), S7,13A NDAT (36 ± 9% of WT) (p<0.001), S4,7,13A NDAT (20 ± 8% of WT) (p<0.01), and S7,12,13A (30 ± 13% of WT) (p<0.001). These results indicate that a large fraction of NDAT in vitro phosphorylation by PKCα occurs on serines 4, 7, and 13, although we cannot eliminate the possibility that mutation of these serines indirectly inhibits phosphorylation of other residues. In addition, the small amount of radioactivity remaining on S4,7,13A indicates the presence of phosphorylation on additional serines.
We also consistently found increased phosphorylation of S2A NDAT by all three kinases, with the PKCα phosphorylation level reaching 158 ± 12% of WT (p<0.001), indicating that Ser2 is not a phosphorylation site but that its mutation alters in vitro phosphorylation of other NDAT residues.
NDAT phosphopeptide mapping analysisBecause NDAT is exclusively phosphorylated by PKA at Ser7 and by CaMKII at Ser13, we 7 developed a strategy to use phosphopeptides derived from these samples as markers in 2D TLC to identify phosphorylation sites on native transporters. To characterize the 2D TLC patterns of NDAT phosphopeptides, 32 P-labeled samples phosphorylated by PKA, CaMKII, or PKCα were immunoprecipitated, gel purified, proteolytically digested, and subjected to 2D TLC in parallel. Proteolysis was performed with trypsin, which cleaves on the C-terminal side of lysine and arginine, plus thermolysin, which cleaves on the N-terminal side of aromatic and bulky hydrophobic residues, to separate all Ser with the exception of Ser12 and Ser13 (Fig. 3A) .
In three independent experiments we found that phospho (p) Ser7 and pSer13 NDAT peptides generated from PKA and CaMKII phosphorylation migrated with clearly distinct patterns (Fig. 3B , left and center panels). Although these NDAT samples are phosphorylated on single serines, 2-3 major and occasional minor fragments were typically generated, indicative of incomplete proteolysis. PKA phosphorylated NDAT peptides containing pSer7 were numbered 1 and 2, and CaMKII phosphorylated NDAT peptides containing pSer13 were numbered 3-6.
The right panel in Figure 3B shows a representative phosphopeptide map of PKCα− phosphorylated NDAT, which contained nine reproducible spots. The spectrum of fragments was consistent with a combination of pSer7 peptides (spots 1 and 2), and pSer13 peptides (spots 3-6), based on alignment of these spots with those from PKA and CaMKII samples, and as supported by Ser7 and Ser13 mutagenesis data. The presence of spots 7-9 not seen in the PKAand CaMKII-NDAT maps supports PKCα phosphorylation of one or more additional residues, possibly Ser4, as indicated by mutagenesis.
Although the NDAT phosphopeptide maps produced in each kinase condition and across multiple experiments showed significant qualitative similarities, slight variations in fragment migration typical of 2D TLC were occasionally seen. Thus to further validate the identity of these peptides and to assess the completeness of digestion with respect to separation of serines, we analyzed PKCα-phosphorylated S7A and S13A NDATs in parallel with PKA-, CaMKII-, and PKCα-phosphorylated WT NDAT samples. In the S7A NDAT sample, spots 1 and 2 were absent (dotted circles) whereas spots 3-9 remained present (Fig. 3C, left) . The findings that spots 1 and 2 align in PKCα-and PKA-phosphorylated NDAT maps and are absent in PKCα-phosphorylated S7A NDAT strongly support the presence of pSer7 in these peptides, and importantly demonstrate that fragments 1 and 2 contain only pSer7 and are not incompletely digested peptides that possess additional phosphorylated residues (e.g., Ser4 or Ser13). Similarly, in PKCα-phosphorylated S13A NDAT, spots 3-6 were absent (dotted circles) while spots 1, 2, and 7-9 remained present, indicating that fragments 3-6 are phosphorylated only on Ser 13 and do not contain Ser7 or other phosphorylated residues (Fig. 3B, right) . The retention of spots 7-9 in both the S7A and S13A samples further verifies the phosphorylation of other NDAT serines.
Rat striatal DAT phosphopeptide mappingWe then used phosphopeptides obtained from PKA-and CaMKII-phosphorylated NDATs as markers in 2D TLC for identification of phosphorylation sites on rat striatal DAT. Phosphorylated DATs were prepared from 32 PO 4 labeled rat striatal slices treated with the diacyl glycerol analog OAG to stimulate PKC-dependent transporter phosphorylation plus the phosphatase inhibitor OA to inhibit transporter dephosphorylation (27) . 32 P-labeled NDAT and rat striatal DAT samples were immunoprecipitated, gel purified, and subjected to proteolysis, 2D TLC, and autoradiography exactly in parallel (Fig. 4) . PKA-phosphorylated NDAT displayed characteristic fragments 1 and 2, and in some experiments three additional fragments (numbered 10-12) that presumably arose from less complete digestion than previous samples (Fig. 8   4A) . A matched phosphopeptide map from rat striatal DAT (Fig. 4B) contained three major and several minor fragments that showed strong similarities to NDAT PKA-and CaMKphosphopeptides, and were numbered 1-4 (and 10-12 when present) based on these similarities. In four independent experiments, alignment of films from DAT and NDAT digests showed essentially complete overlap of major DAT fragments 1 and 2 and minor fragments 10-12, strongly suggesting the identity of these peptides.
To further assess the similarity of these DAT and NDAT phosphopeptides, fragment 1 from each sample was collected from the TLC plate by scraping the cellulose backing corresponding to the spot and eluting the radioactivity from the matrix. Samples were subjected to Cerenkov counting and equal amounts of radioactivity were mixed together and run on a second TLC plate. In three independent experiments we found that the mixed sample chromatographed as a single discrete spot (Fig. 4C) . Because peptides that differ by single amino acids or post-translational modifications can migrate with distinct mobilities in 2D TLC (39) , this result provides extremely strong evidence that spot 1 from PKAphosphorylated NDAT and from metabolically labeled rat striatal DAT contain identical peptides phosphorylated on Ser7.
Fragment 2 in DAT and NDAT samples also showed strong similarity, suggestive of their identity as peptides phosphorylated on Ser7, however we did not perform mixing experiments for these fragments. Peptide 3 from striatal DAT migrated with a clearly distinct mobility from NDAT peptides 1 or 2, suggesting that it represents a distinct phosphopeptide. Migration of DAT peptide 3 was most similar to that of pSer13-containing peptide 3 from CaMKIIphosphorylated NDAT analyzed in parallel (not shown), but in mixing experiments the two fragments separated into closely migrating but distinct species. Thus although we were unable to determine the identity of DAT phosphopeptide 3, its presence and differential mobility from pSer7 NDAT peptides strongly suggests that PKCstimulated phosphorylation of striatal DAT occurs on at least two residues.
Basal and PKC-induced DAT phosphorylation occur on the same residues in neurons -Whereas the preceding experiments were performed using PKC-stimulated DAT samples, we also sought to determine if basal and stimulated DAT phosphorylation occur on the same or different residues. To address this question, we performed 2D TLC of phosphopeptides obtained from rat striatal DATs prepared under basal and PKCstimulation conditions. 32 P-labeled DATs prepared from rat striatal slices treated with vehicle or OA plus OAG were immunoprecipitated, gel purified, digested with trypsin, and desalted by C18 reverse-phase HPLC. The majority of basal and stimulated Cerenkov radioactivity was found in fractions 31-36 ( Fig. 5A, arrow) . These fractions were pooled, concentrated, and subjected to 2D TLC and autoradiography (Fig. 5B) . Note that because these samples were digested with trypsin alone, the pattern is not directly comparable to the striatal sample in Figure 4 .
The digests of basal and stimulated DAT each contained six major phosphopeptides that migrated with essentially identical patterns, with the fragments from treated tissue showing 32 P levels that were increased 2.5-to 4-fold compared to the analogous fragments from the basal sample, as determined by densitometry. The stimulated sample contained no novel fragments compared to the basal sample, and no fragments seen in the basal sample were absent from the stimulated sample. Because stimulated phosphorylation of one or more previously unused sites would result in production of novel phosphopeptides and/or alteration in the charge and thus mobility of fragments compared to the basal state, the similar basal and stimulated phosphopeptide patterns obtained in these experiments strongly indicate that stimulated phosphorylation of striatal DAT occurs on residues that are used under basal conditions. These results thus provide strong evidence that increased phosphorylation of DAT by PKC results from modification of increased numbers of transporters at tonically used sites 9 rather than by de novo phosphorylation of distinct sites.
Identification of Ser7 phosphorylation in expressed rDAT by site-directed mutagenesisAs a further method to determine if Ser7 or Ser13 are phosphorylated, we generated S7A and S13A rDATs for stable expression in LLC-PK 1 cells. Both mutants were expressed as full-length mature protein, and surface biotinylation analyses showed that the total to surface ratios for S7A and S13A forms were comparable to the WT protein (not shown), indicating that the mutants were not defective in surface presentation or maturation. For phosphorylation analyses, cells were metabolically labeled with 32 PO 4 and treated with vehicle or PMA. Because the DAT expression level in each of these cell lines was significantly different, we immunoblotted multiple volumes of each lysate to identify amounts containing equal DAT protein so as to minimize the extent of arithmetical correction needed to normalize phosphorylation intensities to total DAT protein.
The selected volumes were immunoprecipitated and analyzed by SDS-PAGE/autoradiography to determine DAT phosphorylation intensities and were re-blotted to confirm equal DAT levels. WT DAT showed a basal level of phosphorylation that was stimulated ~2-fold (223 ± 35% of basal) by PMA (p<0.05), similar to findings we have previously reported. In six independent experiments we found that S7A DAT showed a trend towards reduced basal phosphorylation (75 ± 9% of WT basal level), a lack of stimulation by PMA treatment (124 ± 24% of WT basal, p>0.05), and a significantly reduced level of PMA-stimulated phosphorylation compared to that of the WT DAT (p<0.05) (Fig.  6) , strongly indicating that Ser7 represents a major site of PKC-dependent phosphorylation on DAT. Conversely, although our 2D TLC findings for striatal DAT were somewhat suggestive of Ser13 usage, analysis of S13A DAT revealed no consistent reduction of phosphorylation intensity in either basal (113 ± 13% of WT basal level, p>0.05) or PMA treatment conditions (248 ± 56% of WT basal level) (p>0.05 relative to WT PMA).
Thus while the significant level of 32 P labeling remaining on S7A DAT protein in both basal and stimulated conditions demonstrates the presence of phosphorylation on one or more additional residues, these experiments do not support phosphorylation of Ser13, and the identity of the other phosphorylated residue(s) remains unknown.
Identification of Ser7 phosphorylation in expressed hDAT by mass spectrometry -To determine if hDAT is also phosphorylated on Ser7, we immunopurified YFP-hDAT from hDAT-HEK293 cell lysates and size fractionated purified proteins by SDS-PAGE (Fig. 7A) . The indicated Coomassie Blue stained bands were subjected to trypsin in-gel digestion and resulting peptides were subjected to liquid chromatography tandem MS (LC-MS/MS). Phosphorylated serine (pS) at position 7 was unambiguously and repeatedly identified within the MS/MS spectra of the tryptic peptide spanning amino acids 4-19 (SKCpSVGLMSSVVAPAK) (Fig. 7B) .
In multiple independent experiments we identified Ser7 from cells treated with OA to inhibit transporter dephosphorylation, while little pSer7 was seen without this treatment, similar to findings of robust OA-stimulated phosphorylation obtained with rDAT. Together with mutagenesis findings, these results confirm the use of Ser7 as a site for basal and PKC/OA-stimulated phosphorylation of heterologously expressed rat and human DAT.
CFT affinity is reduced by mutation of Ser7 and increased by DAT phosphorylation conditions -We next examined mutations of Ser7 and several other N-terminal residues (listed in (Fig. 8A, Table 1 ), indicating that Ser7 and/or its phosphorylation state function to promote high affinity CFT binding. Binding for both forms showed better fit to one-site vs. two-site models. Significant reductions in CFT affinity were also observed with the phosphomimetic substitution of Ser7 to aspartic acid (S7D), and with S4A and Cys (C) 6A mutation (Table 1) , further supporting a role for Ser7 and suggesting that nearby residues also participate in promotion of binding affinity or that their mutations impact Ser7 function. CFT affinity was not altered for S2A, S13A, or T53A DATs, demonstrating a degree of specificity for residues near Ser7 for this effect. Interestingly, Δ21 DAT, a truncation mutant lacking the first 21 N-terminal residues, showed no reduction of CFT affinity, suggesting that Ser4, Cys6, and Ser7 are not required per se for maintenance of high CFT affinity, but rather modulate this property in conjunction with other residues within this domain. B max of CFT binding was not changed for S2A, C6A or S7A DATs, but was reduced up to 2-fold in other mutants (Table 1 ), possibly due to expression level differences.
Because these results were compatible with a role for a demonstrated phosphorylation site in regulating CFT affinity, we then tested the ability of phosphorylation conditions to modulate CFT binding. Similar to some previous reports from heterologous cell systems (40, 41) , we found that treatment of rDAT LLC-PK 1 cells with PMA caused no change in CFT affinity (control K d , 77 ± 18 nM; PMA K d , 81 ± 21 nM; p>0.05) or B max (control, 804 ± 74 fmol/well; PMA, 732 ± 79 fmol/well; p>0.05). However, treatment of rat striatal slices with OA/OAG, which induces the strongest known stimulation of DAT phosphorylation (27) , resulted in a modest but statistically significant increase in CFT binding affinity (K d 45 ± 12 nM) relative to binding obtained from tissue treated with vehicle (K d 63 ± 11 nM), (p<0.05) (Fig. 8B) . No change in binding B max was observed (OA/OAG, 166 ± 14 fmol/mg o.w.w; basal, 159 ± 9 fmol/mg o.w.w.; p>0.05), and binding in both conditions was better fit to one-site vs. two-site models. The findings that Ser7 is phosphorylated in both rat striatal tissue and heterologous cells, that phosphorylation conditions increase CFT affinity in rat striatal tissue, and that mutations preventing Ser7 phosphorylation reduce CFT affinity, strongly support phosphorylation of Ser7 as the mechanism producing these results.
Mutation of Ser7 affects zinc regulation of DAT conformational equilibrium -The binding of CFT to DAT is presumed to reflect the conformational equilibrium of the protein, with the ligand preferentially binding to outwardly facing forms (4, (42) (43) (44) . The findings that CFT affinity is decreased by mutation of Ser7 and nearby residues but increased by DAT phosphorylation conditions thus suggest that the distal N-terminus exerts a phosphorylation-dependent role over the DAT conformational equilibrium that impacts CFT binding. To further explore this possibility, we examined the effect of Ser7 mutations on Zn 2+ modulation of CFT binding, as Zn 2+ binding to DAT leads to dose-dependent augmentation of CFT binding that is thought to reflect stabilization of outwardly facing transporter forms (45, 46) .
For these experiments LLC-PK 1 cells expressing WT, S7A, or S7D rDAT were treated with 1-50 µM Zn 2+ and assayed for [ 3 H]CFT binding (Fig. 9) . In WT DAT, binding was increased by 1-50 µM Zn 2+ (p<0.001 relative to control at all doses), reaching a final level of 156 ± 4% of control at 50 µM Zn 2+ , comparable to previous findings (46) . S7A DAT also showed increased [ 3 H]CFT binding with Zn 2+ treatment (p<0.001 relative to control at all doses), with increases trending toward higher levels than the WT protein at 1, 5, and 10 µM Zn 2+ and reaching a statically greater level than WT DAT (185 ± 7% of control value) at 50 µM Zn 2+ (p<0.01). In contrast, [ 3 H]CFT binding to S7D DAT was not statistically increased at any Zn 2+ concentration (all doses p>0.05), and was significantly different from WT DAT at 5, 10, and 50 µM Zn 2+ (p<0.01) and from S7A DAT at all Zn 2+ concentrations (p<0.001) (Fig. 9) . These results further support a role for Ser7 in regulating CFT binding to DAT,
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with the opposing directions of S7A and S7D effects supporting a functionality of Ser7 phosphorylation in dictating inward and outward conformational equilibria.
DISCUSSION
In this study we identify Ser7 as a PKC phosphorylation site on both rat and human DAT and obtain evidence for a previously unsuspected role for the N-terminal domain and its phosphorylation state in regulating cocaine analog binding. While the distal end of the N-terminal tail has been well characterized as the major PKC phosphorylation domain on DAT (20, 24, 27) , the large number, close spacing, and modification of multiple residues in this region have hampered identification of specific phosphorylation sites. Our findings now support basal and PKCstimulated phosphorylation of Ser7 in both striatal tissue and model cells, as well as demonstrating that significant levels of phosphorylation occur on additional residues that remain currently unknown. Importantly, the identification of pSer7 in both human and rat transporters indicates the conservation of regulatory functions via this site, supporting the appropriateness of rat models for analyses of phosphorylation-dependent functions. We also found no evidence in these studies for phosphorylation of residues not used basally, indicating that functional regulation of DAT by PKC-dependent phosphorylation is achieved by modification of increased numbers of transporters at sites used under basal conditions. While DAT phosphorylation has been investigated primarily for its potential role in PKC-dependent transport down-regulation and AMPH-stimulated efflux (6, 14, 15, 23, 24, 26, 47) , our findings that CFT affinity is decreased by Ser7 mutations and increased by conditions that stimulate Ser7 phosphorylation now adds cocaine binding to this list of functions. Other residues near Ser7 may also participate in this activity, and full investigation of the remaining residues in this region is warranted. Regulation of CFT affinity by PKC-linked inputs thus suggests a mechanism that could potentially impact cocaine binding in vivo and underlie individual responsiveness to cocaine.
Our current understanding of DAT structure indicates that the protein transitions between outwardly facing, occluded, and inwardly facing forms as substrate is transported, with the empty protein returning to the outwardly facing form. Cocaine and its analogs are thought to bind preferentially to outwardly facing conformations within a pocket near the substrate active site generated by residues in TMs 1, 3, 6, and 8 (42, 48, 49) . Based on this model, the CFT affinity reductions induced by Ser7 mutagenesis and CFT affinity increases induced by phosphorylation could be explained by alterations in DAT conformational equilibria that stabilize inwardly or outwardly facing forms. The finding that both S7A and S7D DATs show reduced affinity relative to WT and phosphorylated transporters indicates that although the putative phosphomimetic S7D mutation alters DAT conformation, it does not impart genuine phosphorylation functionality for this activity. In addition, the interpretation that phosphorylation promotes an outwardly facing equilibrium is opposite the current paradigm that postulates promotion of inward conformations by phosphorylation to explain the stimulation of DA efflux by PKC and AMPH (6, 21, 50-52), and further work will be necessary to clarify this issue.
Although mutation of several human DAT residues including Thr62, Trp84, Lys264, Asp313, Tyr335, Asp345, and Asp436 leads to altered CFT affinity attributed to promotion of outwardly or inwardly facing transporter conformations (43, 50, 53, 54) , these residues are located in active site helices and adjacent loops, such that their mutations stabilize intermediate transporter conformations by interfering with TM mobility. Our data now demonstrate that cytoplasmic Nterminal residues that are separated from the active site by both protein and lipid bilayer structure can also impact the binding pocket, and importantly, demonstrate the potential for these effects to be regulated physiologically via Ser7 phosphorylation. Because our binding studies were performed in membranes and in cells held on 12 ice, conditions in which enzyme activities are suppressed and DAT cannot traffic, these results provide strong evidence that DAT kinetic characteristics can be directly impacted by Nterminal phosphorylation.
Additional support for the idea that phosphorylation impacts DAT conformational equilibrium was obtained by our demonstration that Ser7 mutations induced pronounced effects on Zn 2+ regulation of CFT binding. Zn 2+ stimulation of CFT binding to DAT is believed to occur by stabilization of outwardly-facing transporter conformations (45, 46) . If the reduced CFT affinity of S7A DAT occurs via promotion of more inwardly-facing equilibria relative to the WT protein, its increased stimulation of CFT binding relative to WT DAT by Zn 2+ could be consistent with a larger fraction of proteins undergoing inward-to-outward reorientation. The reduced CFT affinity of S7D DAT is also consistent with the mutant possessing a more inwardly facing equilibrium relative to the WT protein. However, lack of S7D DAT responsiveness to Zn 2+ indicates that this mutation produces a more pronounced effect than S7A mutation on transporter conformation that cannot be overcome with Zn 2+ . While additional studies will be necessary to fully understand the mechanisms underlying the effects of these mutations, the findings nevertheless demonstrate a clear effect of negative charge introduction at Ser7, further supporting a phosphorylation-related role for this residue in regulating the transporter active site.
Although Ser7 impacts on conformational equilibria might be expected to affect substrate transport characteristics, we did not see K m alterations for S7A DAT (S7A 2.9 ± 0.5 µM, WT 3.4 ± 0.6 µM, p>0.05) or for WT DATs under PKC conditions (26, 55) . It is possible that the transporter does not reside in specific substratebound states for sufficient duration to allow such alterations to be detected with [ 3 H]DA transport assays, and higher resolution approaches may be useful for testing this. We did note that the degree of affinity change induced by phosphorylation conditions in rat striatum (30% increase) was less than for Ser7 mutation (4-fold reduction), and hypothesize that these differences reflect the stoichiometry of modification, which is 100% for mutation but likely to be considerably lower for phosphorylation. Our finding that PMA treatment of rDAT-LLCPK 1 cells did not produce the CFT affinity increases observed in striatal tissue suggests the presence of mechanistic differences between these systems, potentially including DAT phosphorylation characteristics (sites, stoichiometry, dynamic range), binding partner interactions, or membrane lipid/membrane raft properties (56) , and cell lines with more neuronal characteristics may provide superior model systems for clarifying these issues.
The mechanism by which the DAT distal Nterminus could affect transporter conformational equilibrium is not known, as the three-dimensional structure of this domain and its orientation relative to the intracellular loops have not been determined. One possibility is that the distal Nterminus is positioned in close proximity to intracellular loops where it could impact molecular interactions that occur during the transport cycle. For example, residues Arg60, Ser334, Tyr335, and Asp436 in the proximal N-terminal tail and internal loops 3 and 4 interact through ionic and hydrogen bonds to stabilize the intracellular gate and promote outwardly facing transporter conformations (50, 57) . It is possible that hydrogen bonds from Ser4, Cys6, and Ser7 side groups and/or negative charges from Ser phosphoryl moieties interact with these residues to modulate gate closure and impact transporter equilibrium. Consistent with this idea, recent structural studies on the homologous bacterial transporter LeuT support the generation of an inwardly facing conformation upon transportinduced breakage of the analogous Arg-Asp intracellular gate salt bridge (58) . Alternatively, the distal N-terminus could potentially regulate binding and/or conformational equilibrium by other mechanisms such as impacting the orientation of TM1, which contains residues crucial for cocaine binding (49) , or by regulating 13 interactions with DAT binding partners. For example, syn 1A, which regulates DAT transport, efflux, and channel activity (11) (12) (13) , interacts with DAT via the distal N-terminus (12) and regulates the transporter phosphorylation level (11) . The ability of syn 1A to concomitantly affect DAT phosphorylation and uptake capacity suggests its potential to mechanistically link phosphorylation signals to transport kinetic steps. Other DAT Nterminal binding proteins related to phosphorylation such as receptor for activated C kinase-1 (59) could also represent potential integrators of transporter conformation and phosphorylation.
With respect to the issue of direct vs. indirect kinase actions on DAT, we previously identified many striking similarities between metabolic phosphorylation of DAT and in vitro phosphorylation of NDAT by both PKC and proline directed kinases (28, 29) , supporting NDAT as a good model for elucidating DAT phosphorylation characteristics. In this study we further elucidate multiple NDAT and DAT similarities related to PKC, including the bulk of phosphorylation occurring in the distal N-terminal Ser cluster, phosphorylation occurring on multiple sites within the Ser cluster, and phosphorylation occurring specifically at Ser7. In conjunction with the presence of Ser7 in a canonical PKC motif (R-X-S) (Fig. 1A) , these findings strongly support the ability of PKC to directly phosphorylate Ser7 in vivo and indicate this as a mechanism underlying one or more PKC-dependent responses of DAT.
Although direct demonstration of DAT phosphorylation by PKA and CaMKII has not been shown, DAT is regulated by both of these enzymes (60) (61) (62) (63) , and the robust phosphorylation of NDAT by these kinases supports their potential to phosphorylate DAT.
If this occurs, the phosphorylation of NDAT Ser7 by both PKA and PKC suggests the possibility for this residue to serve as a site for integration of signals from these pathways for regulation of cocaine binding and/or other properties.
Similarly, because AMPHinduced DA efflux has been linked to both CaMKII and PKC (21, 64) , the phosphorylation of NDAT Ser13 by these kinases strongly implicates this residue as a mechanistic locus for efflux and a site for integration for CaMKII and PKC signals . Although we found no reduction of S13A DAT phosphorylation during our 32 P labeling analyses, the conditions used were focused on PKC activation, and it is possible that examination of CaMKII conditions may be more relevant for characterization of this residue as a phosphorylation site.
Numerous studies have now identified the DAT cytoplasmic N-terminus as a major regulatory domain for various transporter functions. Our demonstration of differential phosphorylation of the N-terminus by PKC and proline directed kinases (28, 29) establishes the capacity for distinct kinases to exert effects on DAT and provides a mechanism for integration of signals from multiple pathways. The DAT Nterminus thus represents a major target for regulatory enzymes that impact multiple transporter properties, and further analysis of this region and its complex regulation may provide targets for therapeutic manipulation of transporter function in disease states. 14 DA07390 (RDB). 4 The abbreviations are: Dopamine transporter (DAT), dopamine (DA), neurotransmitter sodium symporter (NSS), protein kinase C (PKC), phorbol 12-myristate 13-acetate (PMA), oleoyl-2-acetylsn-glycerol (OAG), okadaic acid (OA), methamphetamine ( 32 P-labeled PKAphosphorylated NDAT and B, rat striatal DAT were immunoprecipitated, gel purified, and digested with trypsin plus thermolysin, and resulting fragments subjected to 2D TLC and autoradiography. C, Material in spot 1 from each sample was scraped from the TLC plate and eluted from the cellulose matrix. Equal amounts of radioactivity were mixed together, and reanalyzed on a second 2D TLC plate. +, origin Figure 5 . Phosphopeptide maps of basal and PKC-stimulated rat striatal DAT.
32 PO 4 -labeled DATs from rat striatal slices given the indicated treatments were immunoprecipitated, gel purified, and digested with trypsin. A, Tryptic digests of DAT were chromatographed on C18 reverse-phase HPLC and fractions counted by Cerenkov counting. B, Fractions 31-36 from each condition were pooled and subjected to 2D TLC and autoradiography. Results are representative of two independent experiments. +, origin Figure 6 . S7A rDAT displays reduced phosphorylation. Upper panel, LLC-PK 1 cells not transfected with DAT (parent) or expressing WT, S7A or S13A DATs were labeled in parallel with 32 PO 4 for 2h at 37°C, followed by application of vehicle or 1 µM PMA for 30 min at 37°C. Lysates were immunoprecipitated with Ab16 and analyzed by SDS-PAGE and autoradiography or immunoblotting. Lower panel, Histogram showing DAT phosphorylation level normalized for DAT protein, expressed as means ± S.E. of WT basal level set to 100%. *, p<0.05, **, p<0.01 WT PMA or S13A PMA vs. WT basal; †, p<0.05, S13A PMA vs S13A basal; #, p<0.05 S7A PMA vs. WT PMA or S13A PMA (ANOVA followed by Newman-Keuls post hoc test). (S7A n=6, S13A n=8). 
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